Steven Holtzman joined Decibel as president and chief executive officer in 2016. Steve brings more than 30 years of strategic, operational and leadership experience in the biotechnology industry. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc., where he created and led the program leadership and management group through eight new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions.
Prior to Biogen, Steve served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in large scale genetics and genomics, and was a founder, member of the board and the executive vice president of DNX Corporation, the first transgenic animal company. Steve is a member of the boards of directors of Visterra, Humatics, The Sync Project and Molecular Partners. In the not-for-profit arena, Steve is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission.
Steve received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.
Leslie Shinobu joined Decibel in September 2015 serves as chief of translational research. Prior to Decibel, Leslie spent the last two years working behind the scenes to support Third Rock Ventures’ new companies. She couples a passion for making life better for patients with this first-hand experience shaping early company formation, and more than 30 years of translational expertise acquired in both academic and industry settings.
Leslie’s industry experience spans 12 years across biotech and big pharma working on late-stage programs for the multiple sclerosis drugs Avonex, Tysabri, Cladribine (Biogen Idec, Merck Serono) and many early development programs (Biogen Idec, GlaxoSmithKline, Takeda Pharmaceuticals) that have successfully transitioned into the clinic. Her most recent position prior to joining Third Rock was vice president, head of the CNS drug development unit within Takeda.
Leslie completed her Ph.D. in inorganic chemistry at The Center in Environmental Toxicology at Vanderbilt University. Her subsequent medical training at Vanderbilt was followed by residency and chief residency on the neurology service at Massachusetts General Hospital (MGH). She remained on faculty at MGH for over 20 years conducting bench to bedside research and designing clinical programs relevant to movement disorders and amyotrophic lateral sclerosis.
Leslie previously served on the editorial board of the American Society of Experimental Therapeutics and the scientific advisory board of what is now NBIAcure, and worked pro bono for a number of foundations and institutes, including the Huntington Study Group, Common Mind Consortium, Alzheimer Disease Neuroimaging Initiative, the innovation hub MaRS Discovery District, and the Department of Defense Hearing Center of Excellence led Pharmaceutical Interventions for Hearing Loss.
John Keilty joins Decibel from Third Rock Ventures where he served as the general manager of platform operations, responsible for the development and implementation of technology roadmaps for companies across the portfolio. Prior to this role, John was the vice president of information technology and informatics at Infinity Pharmaceuticals where he owned information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. Before joining Infinity in 2002, John was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, with broad ownership for the creation, management, implementation and transfer of many of the company’s core genomic technologies. Before Millennium, John worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing.
John received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.
Ronald Vigliotta joined Decibel as senior director, finance in November 2016 and has more than 20 years of diverse accounting and finance experience, including in both public and private biotechnology companies. Prior to Decibel, Ron served as senior director, finance at Warp Drive Bio for three years, where he led both the accounting and finance functions. Prior to Warp Drive Bio, Ron worked at Infinity Pharmaceuticals for seven years where he held various roles of increasing responsibility including Controller. Before Infinity, he spent five years at Hilb, Rogal and Hobbs, an insurance brokerage company, serving as agency controller. He also worked at Ernst & Young for six years in the assurance and advisory business group servicing clients in multiple industries. Ron graduated from Fairfield University with a bachelor of science in accounting and finance and is a certified public accountant.